As the need for personalized cancer care increases, we face an urgent demand for more accurate biomarker evaluation and more quantitative histopathologic cancer diagnosis to aid and improve therapy decisions. Pathologists need to be equipped with new methodology and tools to deliver the needed diagnostic sensitivity and specificity, and it now seems certain that artificial intelligence (AI) is the next step towards precision pathology. As a biotechnology company pursuing the frontier of science, Creative Biolabs has been focusing on AI applications in IVD for years. With strong foundations, we are capable of providing reliable AI-based biomarker detection services.
Despite the fact that robust guidelines for optimization are in use for several years, biomarker assessment is still limited by the subjectivity linked to (i) defining the appropriate tumor areas to investigate within a heterogenous tissue section; and (ii) the visual interpretation of biomarker distribution and intensity patterns in tumor cells and stromal tissues. Several studies have shown low between-laboratory, inter-observer, and intra-observer reproducibility in biomarker evaluation. This variability is hindering both the process of discovering new biomarkers and their utilization in clinical practice.
Recently, the rapid development of digital microscopy has enabled the digitalization of histological slides at high-resolution and high speed, which can now firmly support training, research, and diagnostics in pathology. The appearance of digital image analysis (DIA) algorithms holds promise to improve the volume precision of histomorphological evaluation. Moreover, digital pathology has recently received increasing attention, partially due to the competition emerging from molecular profiling platforms that deliver precise quantitative results with minimal inter-observer variability problems. The most promising and fundamental advances in computational pathology are based on AI and machine learning methodologies, which deliver computer models with image recognition that match, or outperform, human experts.
Fig.1 Pipeline of tissue sampling and digitization process in pathology. (Acs, 2020)
Committed to the research of in vitro diagnostics (IVD) research over years, Creative Biolabs has never stopped making progress and had thrown our sight into the applications of AI in disease diagnosis. With strong foundations and mature technologies, we are capable of offering comprehensive AI-based application development services in medicine including AI-based biomarker detection development services.
With advantages in various aspects, Creative Biolabs is your best partner. We aspire to bring high-quality services with top-rated customer experiences to every client. If you are interested in AI-based biomarker detection development services or you have any other questions about our services, please feel free to contact us for more information.
For Research Use Only.